Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.

Devin J, Kassambara A, Bruyer A, Moreaux J, Bret C.

J Clin Med. 2019 Jul 22;8(7). pii: E1074. doi: 10.3390/jcm8071074.


Kinome expression profiling to target new therapeutic avenues in multiple myeloma.

de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J.

Haematologica. 2019 Jul 9. pii: haematol.2018.208306. doi: 10.3324/haematol.2018.208306. [Epub ahead of print]


The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.

Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G.

Haematologica. 2019 Jun 20. pii: haematol.2019.222133. doi: 10.3324/haematol.2019.222133. [Epub ahead of print]


Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O, Kassambara A, Moreaux J.

Theranostics. 2019 Jan 1;9(2):540-553. doi: 10.7150/thno.28374. eCollection 2019.


In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells.

Jourdan M, de Boussac H, Viziteu E, Kassambara A, Moreaux J.

J Vis Exp. 2019 Jan 20;(143). doi: 10.3791/58929.


Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.


PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.


Analysis of Global Gene Expression Profiles.

Kassambara A, Moreaux J.

Methods Mol Biol. 2018;1792:157-166. doi: 10.1007/978-1-4939-7865-6_11.


An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.

Szablewski V, Bret C, Kassambara A, Devin J, Cartron G, Costes-Martineau V, Moreaux J.

Oncotarget. 2018 Apr 10;9(27):19079-19099. doi: 10.18632/oncotarget.24901. eCollection 2018 Apr 10.


DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.


Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.


Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.


Characterization of human FCRL4-positive B cells.

Jourdan M, Robert N, Cren M, Thibaut C, Duperray C, Kassambara A, Cogné M, Tarte K, Klein B, Moreaux J.

PLoS One. 2017 Jun 21;12(6):e0179793. doi: 10.1371/journal.pone.0179793. eCollection 2017.


Hypoxia favors the generation of human plasma cells.

Schoenhals M, Jourdan M, Bruyer A, Kassambara A, Klein B, Moreaux J.

Cell Cycle. 2017 Jun 3;16(11):1104-1117. doi: 10.1080/15384101.2017.1317408. Epub 2017 May 2.


Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.

Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J.

Nucleic Acids Res. 2017 Jun 2;45(10):5639-5652. doi: 10.1093/nar/gkx327.


[Maxillary ameloblastoma at the odonto-stomatology University Hospital in Bamako].

Ba B, Keita K, Coulibaly A, Ba M, Touré A, Koita H, Kassambara A, Théra TD, Guindo M, Diallo M, Coulibaly DT, Diombana ML.

Mali Med. 2017;32(2):1-8. French.


Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage.

Schoenhals M, Jourdan M, Seckinger A, Pantesco V, Hose D, Kassambara A, Moreaux J, Klein B.

Cell Cycle. 2016 Jul 17;15(14):1919-28. doi: 10.1080/15384101.2016.1191709. Epub 2016 May 26.


RECQ helicases are deregulated in hematological malignancies in association with a prognostic value.

Viziteu E, Kassambara A, Pasero P, Klein B, Moreaux J.

Biomark Res. 2016 Feb 13;4:3. doi: 10.1186/s40364-016-0057-4. eCollection 2016.


Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.

Bret C, Viziteu E, Kassambara A, Moreaux J.

Expert Rev Hematol. 2016;9(4):351-60. doi: 10.1586/17474086.2016.1141673. Epub 2016 Feb 12. Review.


Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.


Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, Cartron G, Moreaux J, Hose D, Klein B.

Oncotarget. 2015 Mar 20;6(8):6431-47.


In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.


GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells.

Kassambara A, Rème T, Jourdan M, Fest T, Hose D, Tarte K, Klein B.

PLoS Comput Biol. 2015 Jan 29;11(1):e1004077. doi: 10.1371/journal.pcbi.1004077. eCollection 2015 Jan.


A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.

Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B.

Oncotarget. 2014 May 15;5(9):2487-98.


DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Gourzones-Dmitriev C, Kassambara A, Sahota S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B.

Cell Cycle. 2013 Sep 1;12(17):2760-73. doi: 10.4161/cc.25951. Epub 2013 Aug 9. Review.


Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.

PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.


Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D, Klein B.

Haematologica. 2013 Sep;98(9):1442-9. doi: 10.3324/haematol.2012.066944. Epub 2013 Apr 12.


Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal.

Ramirez JM, Bai Q, Péquignot M, Becker F, Kassambara A, Bouin A, Kalatzis V, Dijon-Grinand M, De Vos J.

Stem Cells Dev. 2013 Jun 15;22(12):1851-60. doi: 10.1089/scd.2012.0658. Epub 2013 Mar 5.


STEAP1 is overexpressed in cancers: a promising therapeutic target.

Moreaux J, Kassambara A, Hose D, Klein B.

Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):148-55. doi: 10.1016/j.bbrc.2012.10.123. Epub 2012 Nov 6.


Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.

Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.

PLoS One. 2012;7(7):e42161. doi: 10.1371/journal.pone.0042161. Epub 2012 Jul 31.


Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.

Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.


Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation.

Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B.

J Immunol. 2011 Oct 15;187(8):3931-41. doi: 10.4049/jimmunol.1101230. Epub 2011 Sep 14.


Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

Bret C, Hose D, Reme T, Kassambara A, Seckinger A, Meissner T, Schved JF, Kanouni T, Goldschmidt H, Klein B.

Exp Hematol. 2011 May;39(5):546-557.e8. doi: 10.1016/j.exphem.2011.02.002. Epub 2011 Mar 3.


Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Moreaux J, Hose D, Kassambara A, Reme T, Moine P, Requirand G, Goldschmidt H, Klein B.

Blood. 2011 Jan 27;117(4):1280-90. doi: 10.1182/blood-2010-04-279760. Epub 2010 Nov 19.


Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, Goldschmidt H, Klein B.

Leukemia. 2010 Nov;24(11):1940-50. doi: 10.1038/leu.2010.192. Epub 2010 Sep 16.


Embryonic stem cell markers expression in cancers.

Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B.

Biochem Biophys Res Commun. 2009 May 29;383(2):157-62. doi: 10.1016/j.bbrc.2009.02.156. Epub 2009 Mar 4.


The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B.

Blood. 2009 May 7;113(19):4614-26. doi: 10.1182/blood-2008-07-170464. Epub 2009 Feb 18.


MMSET is overexpressed in cancers: link with tumor aggressiveness.

Kassambara A, Klein B, Moreaux J.

Biochem Biophys Res Commun. 2009 Feb 20;379(4):840-5. doi: 10.1016/j.bbrc.2008.12.093. Epub 2008 Dec 31.

Supplemental Content

Loading ...
Support Center